Abstract | BACKGROUND: PATIENTS AND METHODS: RESULTS: 55 pts (median age 56 yrs) were evaluable for a final analysis with a median observation time of 9.3 years. The CR-rate was 77.4% ; the 5 and 8-year-EFS rates were 46.4% (95%CI 32.5-60.3%) and 43.5% (29.4-57.6%), respectively, and the 5- and 8 yr OS rates were 64.6% (51.7-77.5%) and 59.9% (46.4-73.4%). 14/55 patients have died due to lymphoma progression, and 2/55 patients (3.6%) due to treatment related toxicity, 4/55 due to other causes (3 infections, 1 acute heart failure). In a matched pair analysis comparing CHOEP-14 and CIVEP-14, CIVEP-14 had a higher hematotoxicity with no significant differences in the event free and overall survival for the two regimens. CONCLUSIONS:
|
Authors | Karin Hohloch, Carsten Zwick, Marita Ziepert, Dirk Hasenclever, Ulrich Kaiser, Andreas Engert, Heinz-Gert Höffkes, Frank Kroschinsky, Rolf Mesters, Andreas C Feller, Markus Löffler, Lorenz Trümper, Michael Pfreundschuh, German High-Grade Non-Hodgkin´s Lymphoma Study Group (DSHNHL) |
Journal | SpringerPlus
(Springerplus)
Vol. 3
Pg. 5
(Jan 03 2014)
ISSN: 2193-1801 [Print] Switzerland |
PMID | 24455463
(Publication Type: Journal Article)
|